Xcout Intel
Immunis, Inc.
Immunis, Inc. is a private, clinical-stage biotechnology company founded in 2019 and headquartered in Irvine, California, pursuing novel secretome-based therapeutics for age-related diseases.
Subscribe to see Immunis, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
Immunis, Inc. at a glance
Immunis, Inc. is a biotechnology company headquartered in United States. It has raised at least $32.4M across the 2 funding rounds on record. Its most recent funding round raised $12M in May 2026. Xcout tracks 13 named people at Immunis, Inc., including Hans Keirstead (President).
Immunis, Inc. leadership
- Hans KeirsteadPresident
- Mark CabatoChief Business Officer
- Tom LaneChief Science Officer
- Hans S. KeirsteadChairman
- Mihaela (Mani) NistorVP of Regulatory and Clinical Compliance
- Erin CurryDirector of Medical Affairs
7 more named people on record for Immunis, Inc., with roles, board committees and tenure — see the full roster →
Immunis, Inc. funding rounds
At least $32.4M raised across the 2 rounds on record. Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| SEC Form D filing | $12M | — | |
| SEC Form D filing | $20.4M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Immunis, Inc. competitors
A few of Immunis, Inc.'s closest competitors — see the full list of competitors and alternatives →
Secretome Therapeutics, Inc. is a biotechnology and holding company located in Texas, United States, operating in the drug pipeline and therapeutics sector.
Deciduous Therapeutics, Inc. is a biotechnology startup located in San Francisco, California, focused on developing novel therapeutics targeting aging and immune dysfunction.
TECregen AG is a biotechnology company headquartered in Basel, Switzerland. The company is dedicated to advancing immuno-rejuvenation through the development of next-generation therapies designed to regenerate the thymus.
Autonomy Bio Inc. is a biotechnology company focused on developing human aging therapeutics aimed at extending healthspan and mitigating age-related decline. The company targets individuals seeking to maintain health and independence as they age.
Immunitas Therapeutics, Inc. is a US-based biotechnology company established in 2019 and headquartered in Waltham, Massachusetts. The company focuses on pioneering novel therapeutic treatments in immunology and oncology.
Get Immunis, Inc.'s news by email
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Share this card
Post the link and the card appears automatically — each network fetches the image itself.
More on Immunis, Inc. in Xcout Intel
- 13 named people with titles, LinkedIn and board committees
- 2 funding rounds with the investors in each, and who they co-invest with
- The full competitor set, tracking, exports and API access